HOME / CONTACT US
繁體版 / 简体版
 

Board of Directors

The company has seven to nine directors and adopts a candidate nomination system. The term of office is three years. The shareholders will elect from the list of candidates, and they may be re-elected. The company elected the eighth board of directors (7 directors, including 4 independent directors) at the general meeting of shareholders in August 2021, with a term of office from August 20, 2021 to August 19, 2024. In order to establish a good governance system for the board of directors of the company, improve supervision functions and strengthen management functions, the "Rules of Procedures for the Board of Directors of Public Offering Companies" have been formulated for compliance.
 
Directors Biographies:

Chairman
Kuo, Hsien-Shou
Current Position(s):
  • Independent Director, TaiRx, Inc.
  • Emeritus Professor, Taipei Medical University
Experience:
  • žRepresentative juristic-person director, Oneness biotech Co., Ltd.
  • Professor, Taipei Medical University
Education:
  • PhD of Faculty of Pharmacy and Pharmaceutical Sciences, Meijo University
 
Director
Huang, Cheng Chun
Current Position(s):
  • Director, Microbio Co., Ltd.
  • žSupervisor, Hedonist Biochemical Technologies Co., Ltd.
Experience:  
  • Audit Manager, Chung-Ching Textile Co., Ltd.
  • Vice President of Administration Department, Wagon Group
Education:
  • žTamsui Institute of Business Administration
 
Director
Yang, Pan Chyr
žCurrent Position(s):
  • Director, Microbio Co., Ltd.
  • Dean, College of Medicine, National Taiwan University
  • Professor, Department of Internal Medicine, College of Medicine, National Taiwan University
  • Program Director, Microarray Core Facility, National Research Program for Genomic Medicine
Experience:
  • President, National Taiwan University
  • Director, NTUH National Clinical Trial and Research Center
  • President, Taiwan Society of Pulmonary and Critical Care Medicine
Education:
  • M.D., College of Medicine, National Taiwan University
  • Ph.D., Graduate Institute of Clinical Medicine, National Taiwan University
 
Independent Director
Lai, Yuan Ho
Current Position(s):
  • Independent Director, Microbio Co., Ltd.
  • Director, Chilisin Electronics Corp.
  • Supervisor, Kaimei Electronics Corp.
  • Supervisor, Global Testing Corp.
  • Honorary Professor, College of Law, National Chengchi University
Experience:
  • Dean, College of Law, National Chengchi University Director,
  • Chairman, Chilisin Electronics Corp.
  • Chairman, Teapo Electronic Corporation
  • Consultant, Fair Trade Commission, Executive Yuan
Education:
  • Bachelor of Laws, National Taiwan University
  • Ph.D., College of Law, Kobe University
 
Independent Director
Tsai, Kao Chung
Current Position(s):
  • žIndependent Director, Microbio Co., Ltd.
  • žChairman, Champion Microelectronic Corp.
  • žDirector, Glyconex Inc.
  • žIndependent Director, Holy Stone Healthcare Co., Ltd.
Experience:
  • žVice president of Underwriting Department, Barits Securities Corporation
  • Manager of Underwriting Department, Taiwan International Securities Co.,LTD.
Education:
  • žMaster of Department of Economics, Soochow University
 
Independent Director
Han, Li Chun
Current Position(s):
  • žIndependent Director, Microbio Co., Ltd.
  • Independent Director, StemCyte International Ltd.
  • Chairman, President Futures Co., Ltd.
Experience:
  • ž Vice president of Brokerage Business, President Securities Corp
  • Director, President Futures Co., Ltd.
  • Supervisor, President Futures Co., Ltd.
Education:
  • žDepartment of Economics, National Chung Hsing University
 
Independent Director
Liang, Chi-Ming
Current Position(s):
  • Distinguished Visiting Chair,  Biomedical Translation Research Center of Academia Sinica, Taiwan
  • Concurrent Chair Professor, College of Life Sciences, Kaohsiung Medical University
Experience:
  • Director, Office of Public Affairs and Technology Transfer of Academia Sinica, Taiwan  
  • Co-principal investigators, Taiwan Biobank of Academia Sinica, Taiwan
  • Adjunct research fellow, Genomic Research Center of Academia Sinica, Taiwan
  • Adjunct Director, Genomic Research Center Incubation Center of Academia Sinica, Taiwan
Education:
  • Master of Chemistry , National Taiwan University
  • PhD. of Pharmacology, University of Arkansas for Medical Sciences
(note):Kingbird Tech Co., Ltd. reappointed Mr. Kuo, Hsien-Shou as the representative. And the BOD re-elected him as the chairperson of the board on December 20, 2021.
 
 
The implementation of diversity by board members

The company stipulates in the "Code of Practice on Corporate Governance" that the composition of the board of directors should be diversified. Except for directors who are also managers of the company, it is not advisable to exceed one-third of the number of directors, and it should formulate appropriate diversification policies based on its own operation, operation type and development needs.
 
Among the current 7 board members of the company (including 4 independent directors), concurrently serving as company managers.
 
It is mentioned in the Company's "Code of Practice on Corporate Governance" that board members should generally possess the knowledge, skills and literacy necessary to perform their duties. In order to achieve the ideal goal of corporate governance, the overall board of directors should have the following capabilities:
 
1. Operational judgment ability.
2. Legal, Accounting and financial analysis capabilities.
3. Operation and management capabilities.
4. Crisis management capabilities.
5. Industry knowledge.
6. International market outlook.
7. Leadership.
8. Decision-making ability.
  
In summary, the overall capabilities of the company's board of directors have complied with the diversification policy stipulated in the Code.
 
 
Results of the most recent annual board performance evaluation

The company formulated the "Self-Evaluation or Peer Evaluation of the Board of Directors" on August 11, 2015, and conducted regular board performance evaluation tasks in accordance with the regulations rigorously. The performance evaluation of the board of directors in 2020 has been completed. The Compensation committee had evaluated according to the indicators listed in the method, and the evaluation results will report to the board of directors meeting of 2021 (held on April 16, 2021) and the Compensation committee meeting of 2021 (held on of December 20, 2021).
 
The measurement items of the performance evaluation of the company's board of directors include the following five aspects:
1.      Participation in the operation of the company;
2.      Improvement of the quality of the board of directors' decision making;
3.      Composition and structure of the board of directors;
4.      Election and continuing education of the directors; and
5.      Internal control.
 
The year 2020 board performance evaluation result was excellent. According to the evaluation results, the overall operation of the board of directors is still good.
 
The company revised the "Self-Evaluation or Peer Evaluation of the Board of Directors" on November 13, 2020, which clearly stipulates that the Company's board performance evaluation shall be conducted by an external independent professional institution or a panel of external experts and scholars at least once every three years.. In 2020, the "Taiwan Institute of Ethical Business and Forensics" was appointed to perform the performance evaluation of the board of directors. For details, please refer to the following link:
 
2020 Annual Board Performance External Evaluation PDF

In addition, the company has disclosed the "Self-Evaluation or Peer Evaluation of the Board of Directors" on the company website for inquiries. 

Succession Plan: please refer to the following link:

Succession Plan PDF